Cardiovascular Research Advance Access [Accepted Manuscript] published online on February 13, 2009
Cardiovascular Research, doi:10.1093/cvr/cvp061
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prevention of cardiomyopathy in 
-sarcoglycan knock-out mice after systemic transfer of targeted adeno-associated viral vectors
1 Internal Medicine III, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
2 Applied Tumorvirology, German Cancer Research Center, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany
3 Institute of Human Genetics, University of Newcastle upon Tyne, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK
Correspondence should be addressed to: Dr. Oliver J. Müller University Hospital Heidelberg Internal Medicine III Im Neuenheimer Feld 410 69120 Heidelberg Germany Phone +49 6221 5639401 Fax +49 6221 564866 E-mail: oliver.mueller{at}med.uni-heidelberg.de
Aim: 
-Sarcoglycan is a member of the dystrophin-associated glycoprotein complex linking the cytoskeleton to the extracellular matrix. Similar to patients with defects in the gene encoding -sarcoglycan (Sgcd), knock-out mice develop cardiomyopathy and muscular dystrophy. The aim of our study was to develop an approach for preventing cardiomyopathy in Sgcd-deficient mice by cardiac expression of the intact cDNA upon systemic delivery of adeno-associated viral (AAV) vectors.
Methods: We packaged the Sgcd cDNA under transcriptional control of a myosin light chain-promoter fused with a cytomegalovirus enhancer into AAV-9 capsids. Vectors carrying either the Sgcd cDNA or an enhanced green fluorescent protein (EGFP) reporter gene were intravenously injected into adult Sgcd knock-out mice.
Results: After 6 months, immunohistochemistry revealed almost complete reconstitution of the sarcoglycan subcomplex in heart but not skeletal muscle of mice with the Sgcd vector. Furthermore, Sgcd gene transfer resulted in prevention of cardiac fibrosis and significantly increased running distance measured by voluntary wheel running. Left ventricular function remained stable in mice expressing Sgcd while it deteriorated in EGFP controls within 6 months, paralleled by increased expression of brain natriuretic peptide, a molecular marker of heart failure.
Conclusion: Our study establishes an approach to specifically treat hereditary cardiomyopathies by targeting gene expression into the myocardium upon systemic application of AAV vectors.
KEYWORDS gene therapy; cardiomyopathy; heart failure; myocardium
Time for primary review: 25 Days
Subject codes: [88] Gene therapy, [130] Animal models of human disease, [145] Genetically altered mice, [16] Myocardial cardiomyopathy disease, [11] Other heart failure
Related Article
CiteULike 
Connotea 
Del.icio.us What's this?
Cardiovasc Res 2009 82: 383-384.
This article has been cited by other articles:
|
|
 |
|
  M. Periasamy and J. A. Rafael-Fortney Somatic gene therapy to treat heart failure is one step closer to reality Cardiovasc Res, June 1, 2009; 82(3): 383 - 384. [Full Text] [PDF]
|
|